Metsera, Inc.

$70.50

$0.25(-0.35%)

Metsera, Inc.

MTSR

$70.50

$0.25(-0.35%)

Metsera, Inc.

MTSR

NASDAQ

$70.50

$0.25(-0.35%)

Chart

Upcoming Earnings

Next report date

Mar 25, 2026

Report period

Q1 2026

EPS Estimate

$-0.54

Revenue Estimate

—

Key stats

52-Week Range$70.50

$12.30

$83.86

Market capitalization

$7.43B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-23.55

Basic EPS (TTM)

$-3.02

Net income (TTM)

$-314.41M

Revenue (TTM)

$0.00

Avg. volume

3.50M

Beta (1Y)

1.70

Employees

Market capitalization

$7.43B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-23.55

Basic EPS (TTM)

$-3.02

Net income (TTM)

$-314.41M

Revenue (TTM)

$0.00

Avg. volume

3.50M

Beta (1Y)

1.70

Employees

Screener Quick Check

About Metsera, Inc.

Sector

Healthcare

Industry

Biotechnology

CEO

Christopher Whitten Bernard

Website

metsera.com

Headquarters

3 World Trade Center, New York City, NY, 10007

IPO Date

2025-01-31

Identifiers

ISINUS59267L1070

Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to...

Related Stocks

Axsome Therapeutics, Inc.

AXSM

$158.23Mkt Cap: $8.09B

Healthcare

Biotechnology

ISIN:US05464T1043

Abivax S.A.

ABVX

$122.75Mkt Cap: $8.05B

Healthcare

Biotechnology

ISIN:US00370M1036

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q1 '26

Actual

Estimate

Earnings

Next: Q1 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q1 '26

Actual

Estimate

Earnings

Next: Q1 '26

Actual

Estimate